Improvement of psoriasis by a topical vitamin D3 analo

British Journal of Dermatology 119, 223-230

DOI: 10.1111/j.1365-2133.1988.tb03204.x

Citation Report

#	Article	IF	CITATIONS
1	Chapter 19. Advances in Dermatology. Annual Reports in Medicinal Chemistry, 1989, , 177-186.	0.5	8
2	Will 1,25-Dihydroxyvitamin D3, MC 903, and Their Analogues Herald a New Pharmacologic Era for the Treatment of Psoriasis?. Archives of Dermatology, 1989, 125, 1692.	1.7	30
3	Treatment of Psoriasis by the Topical Application of the Novel Cholecalciferol Analogue Calcipotriol (MC 903). Archives of Dermatology, 1989, 125, 1647.	1.7	129
4	1,25-Dihydroxyvitamin D3 and the Skin: A Unique Application for the Treatment of Psoriasis. Experimental Biology and Medicine, 1989, 191, 246-257.	1.1	28
5	A double-blind study of topical $1\hat{l}\pm,25$ -dihydroxyvitamin D3 in psoriasis. British Journal of Dermatology, 1989, 120, 661-664.	1.4	55
6	A double-blind, placebo-controlled trial of topical 1,25-dihydroxycholecalciferol in psoriasis. British Journal of Dermatology, 1989, 121, 493-496.	1.4	29
7	Vitamin D ₃ in Dermatology: A Critical Appraisal. Dermatology, 1989, 178, 184-188.	0.9	23
8	DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 nalogue MC903 and betamethasone. British Journal of Dermatology, 1990, 123, 291-295.	1.4	61
9	Effect of 1,25-dihydroxyvitamin D3 on human keratinocytes grown under different culture conditions. In Vitro Cellular & Developmental Biology, 1990, 26, 379-387.	1.0	59
10	Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Archives of Dermatological Research, 1990, 282, 164-167.	1.1	141
11	Phototherapy and Photochemotherapy. New England Journal of Medicine, 1990, 322, 1149-1151.	13.9	26
12	Dermatologic therapy: December 1987 to December 1988. Journal of the American Academy of Dermatology, 1990, 22, 231-238.	0.6	O
13	Comparative effects of a novel Vitamin D Analogue MC-903 and 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity, osteocalcin and DNA synthesis by human osteoblastic cells in culture. Bone, 1990, 11, 171-179.	1.4	34
14	Inverse relation between severity of psoriasis and serum 1,25-dihydroxyvitamin D level. Journal of Dermatological Science, 1990, 1, 277-282.	1.0	31
15	Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet, The, 1991, 337, 196-200.	6.3	280
16	Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet, The, 1991, 337, 193-196.	6.3	362
17	Calcipotriol (MC 903): Pharmacokinetics in rats and biological activities of metabolites. Biochemical Pharmacology, 1991, 41, 1601-1606.	2.0	97
18	EFFICACY AND TOLERABILITY OF CALCIPOTRIOL IN PSORIASIS. , 1991, , 417-423.		2

#	Article	IF	Citations
19	Vitamin D Therapy in Psoriasis. DICP: the Annals of Pharmacotherapy, 1991, 25, 835-839.	0.2	9
20	FORMULATION OF 1-ALPHA,25-DIHYDROXYCHOLECALCIFEROL TOPICAL OINTMENT FOR PSORIASIS TREATMENT. Australasian Journal of Dermatology, 1991, 32, 107-110.	0.4	O
21	Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. British Journal of Dermatology, 1991, 124, 221-229.	1.4	78
22	The induction of epidermal ornithine decarboxylase following tape stripping is inhibited by a topical vitamin D3 analogue (MC903). British Journal of Dermatology, 1991, 125, 6-8.	1.4	14
23	Topical treatment with the vitamin D3 analogue MC903 improves pityriasis rubra pilaris: clinical and immunohisto chemical observations. British Journal of Dermatology, 1991, 125, 293-294.	1.4	12
24	Contact dermatitis from MC 903, a topical vitamin D3analogue. Contact Dermatitis, 1991, 25, 139-139.	0.8	45
25	1,25-Dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. Differentiation, 1991, 47, 173-188.	1.0	45
26	Studies on psoriatic osteopathy. Clinical Rheumatology, 1991, 10, 13-17.	1.0	19
27	Regulation of cell growth, c-myc mRNA, and 1,25-(OH)2 vitamin D3 receptor in C3H/10T1/2 mouse embryo fibroblasts by calcipotriol and 1,25-(OH)2 vitamin D3. European Journal of Endocrinology, 1992, 126, 75-79.	1.9	8
28	Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line Gut, 1992, 33, 1660-1663.	6.1	91
29	1, 25-Dihydroxyvitamin D3 for the Treatment of Psoriasis. Journal of Nutritional Science and Vitaminology, 1992, 38, 84-87.	0.2	1
30	$1\hat{l}\pm$, 25-Dihydroxyvitamin D ₃ (calcitriol) ointment in psoriasis. Journal of Dermatological Treatment, 1992, 3, 177-180.	1.1	24
31	Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. Journal of the American Academy of Dermatology, 1992, 26, 736-743.	0.6	196
32	Calcipotriol. Drugs, 1992, 43, 415-429.	4.9	45
33	Treatment of psoriasis with calcipotriol and other vitamin D analogues. Journal of the American Academy of Dermatology, 1992, 27, 1001-1008.	0.6	78
34	Cutaneous and Ocular Ramifications of Ultraviolet Radiation. Dermatologic Clinics, 1992, 10, 483-504.	1.0	4
35	Vitamin D3 and skin diseases. Archives of Dermatological Research, 1992, 284, S30-S36.	1.1	31
36	The use of calcipotriol in HIV-related psoriasis. Clinical and Experimental Dermatology, 1992, 17, 342-343.	0.6	21

#	Article	IF	CITATIONS
37	CALCIPOTRIOL AND PSORIASIS. International Journal of Dermatology, 1992, 31, 549-550.	0.5	2
38	A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. British Journal of Dermatology, 1992, 127, 266-271.	1.4	138
39	Vitamin D analogues and psoriasis. British Journal of Dermatology, 1992, 127, 71-78.	1.4	63
40	Progress in self treatment for psoriasis vulgaris. Journal of Clinical Pharmacy and Therapeutics, 1992, 17, 217-222.	0.7	3
41	Vitamin D analogues in the treatment of psoriasis. Journal of Cellular Biochemistry, 1992, 49, 46-52.	1.2	70
42	1,25-dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-?1 on human keratinocytes in culture. Journal of Cellular Physiology, 1992, 151, 579-587.	2.0	63
43	Vitamin D analogues, marrow fibrosis and psoriasis. British Journal of Dermatology, 1993, 128, 359-359.	1.4	3
44	Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. British Journal of Dermatology, 1993, 128, 566-571.	1.4	60
45	Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. British Journal of Dermatology, 1993, 128, 666-673.	1.4	66
46	Serum calcium and phosphorus measurements in patients with psoriasis: a retrospective review. Journal of the European Academy of Dermatology and Venereology, 1993, 2, 18-21.	1.3	1
47	Structure and absolute configuration of a monohydrate of calcipotriol, $(1\hat{1}\pm,3\hat{1}^2,5Z,7E,22E,24S)$ -24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol. Acta Crystallographica Section C: Crystal Structure Communications, 1993, 49, 618-621.	0.4	4
48	Efficacy of Vitamin D3 Derivatives in the Treatment of Psoriasis Vulgaris: A Preliminary Report. Mayo Clinic Proceedings, 1993, 68, 835-841.	1.4	26
49	Skin diseases. Reviews in Clinical Gerontology, 1993, 3, 245-258.	0.5	0
50	Divergent effects of epidermal growth factor and calcipotriol on human rectal cell proliferation Gut, 1994, 35, 1742-1746.	6.1	8
51	Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis Gut, 1994, 35, 1718-1720.	6.1	12
52	A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. British Journal of Dermatology, 1994, 131, 673-677.	1.4	70
53	Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf 81
54	Calcipotriol improves the response of psoriasis to PUVA. British Journal of Dermatology, 1994, 130, 79-82.	1.4	107

#	Article	IF	Citations
55	Skin lesions in psoriasis. Bailliere's Clinical Rheumatology, 1994, 8, 295-316.	1.0	11
56	The interleukin-8 receptor: a potential target for antipsoriatic therapy?. European Journal of Pharmacology, 1994, 258, 269-272.	1.7	25
57	Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. Journal of the American Academy of Dermatology, 1994, 31, 755-759.	0.6	100
58	Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha ($\text{IL-}1^{\pm}$) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). Journal of Dermatological Science, 1994, 7, 24-31.	1.0	41
59	Nail psoriasis treated with calcipotriol (MC 903): an open study. Journal of Dermatological Treatment, 1994, 5, 149-150.	1.1	23
60	Calcitriol ($1\hat{1}\pm$,25-Dihydroxyvitamin D_{3}) Ointment in Psoriasis, a Safety Tolerance and Efficacy Multicentre Study. Dermatology, 1994, 188, 135-139.	0.9	16
62	IL- $1\hat{l}\pm$, IL-6 and TNF- $\hat{l}\pm$ in Cutaneous Lesions of Lupus Erythematosus are Inhibited by Topical Application of Calcipotriol. International Journal of Immunopathology and Pharmacology, 1995, 8, 199-207.	1.0	2
63	In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. British Journal of Dermatology, 1995, 133, 168-175.	1.4	43
64	Structure-Function Relationships in the Vitamin D Endocrine System*. Endocrine Reviews, 1995, 16, 200-257.	8.9	821
65	Pilot Study of Topical Calcitriol (1,25-Dihydroxyvitamin D3) for Treating Psoriasis in Children. Archives of Dermatology, 1995, 131, 961.	1.7	19
66	Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Journal of the American Academy of Dermatology, 1995, 32, 67-72.	0.6	70
67	Stimulation of epidermal proliferation in mice with $1\hat{l}_{\pm}$,25-dihydroxyvitamin D3 and receptor-active 20-epi analogues of $1\hat{l}_{\pm}$,25-dihydroxyvitamin D3. Biochemical Pharmacology, 1995, 49, 621-624.	2.0	48
68	1,25-Dihydroxyvitamin D3 increased \hat{l}^2 -adrenergic adenylate cyclase response of fetal rat keratinizing epidermal cells (FRSK cells). Journal of Dermatological Science, 1996, 11, 121-128.	1.0	8
69	The vitamin D3analogue, calcipotriol, induces sphingomyelin hydrolysis in human keratinocytes. FEBS Letters, 1996, 378, 88-92.	1.3	54
70	Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. Journal of the American Academy of Dermatology, 1996, 34, 429-433.	0.6	20
71	Immunohistochemical Detection of 1,25-dihydroxyvitamin D3 Receptors (VDR) in Human Skin. Pathology Research and Practice, 1996, 192, 281-289.	1.0	26
72	$1\hat{l}\pm,25$ -Dihydroxyvitamin D3; its role for homeostasis of keratinocytes. Journal of Nutritional Biochemistry, 1996, 7, 642-649.	1.9	2
73	Safety and efficacy of calcipotriol ointment (Dovonex®) in treating children with psoriasis vulgaris. British Journal of Dermatology, 1996, 135, 390-393.	1.4	16

#	Article	IF	CITATIONS
74	Topical calcipotriol in the treatment of intertriginous psoriasis. British Journal of Dermatology, 1996, 135, 647-650.	1.4	20
75	Safety and efficacy of oral calcitriol (1, 25 -dihydroxyvitamin D3) for the treatment of psoriasis. British Journal of Dermatology, 1996, 134, 1070-1078.	1.4	53
76	All-trans retinoic acid inhibits binding of 1,25-dihydroxy-vitamin D3 to the vitamin D receptor in cultured human keratinocytes. Experimental Dermatology, 1996 , 5 , $24-27$.	1.4	7
77	Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D ³) for the treatment of psoriasis. British Journal of Dermatology, 1996, 134, 238-246.	1.4	73
78	The vitamin D endocrine system and its therapeutic potential. Advances in Drug Research, 1996, 28, 269-312.	0.8	63
79	Calcipotriene Ointment Applied Once a Day for Psoriasis: A Double-Blind, Multicenter, Placebo-Controlled Study. Archives of Dermatology, 1996, 132, 1527.	1.7	12
80	Calcipotriol in psoriasis - as monotherapy and in combinations. Journal of Dermatological Treatment, 1997, 8, 261-263.	1.1	1
81	Skin diseases. Reviews in Clinical Gerontology, 1997, 7, 31-45.	0.5	0
82	Calcipotriol in the Treatment of Psoriasis of Limited Severity: Pharmacoeconomic Evaluation. Journal of Cutaneous Medicine and Surgery, 1997, 2, 7-15.	0.6	10
83	1,25-Dihydroxyvitamin D3 and a new analogue, 22-oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratinocytes. Journal of Dermatological Science, 1997, 15, 207-213.	1.0	29
84	Vitamin D3 analogues. Clinics in Dermatology, 1997, 15, 705-713.	0.8	31
85	History of treatments. Clinics in Dermatology, 1997, 15, 693-703.	0.8	5
86	Effect of a topical corticosteroid, a retinoid and a vitamin D3derivative on sodium dodecyl sulphate induced skin irritation. Contact Dermatitis, 1997, 37, 19-26.	0.8	38
87	Expression of integrin subunits and CD44 isoforms in psoriatic skin and effects of topical calcitriol application. Journal of Cutaneous Pathology, 1997, 24, 499-506.	0.7	9
88	Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Archives of Dermatological Research, 1997, 289, 559-566.	1.1	103
89	Psoriasis and calcipotriol: an overview. International Journal of Dermatology, 1997, 36, 255-258.	0.5	5
90	Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. British Journal of Dermatology, 1997, 136, 89-93.	1.4	13
91	Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis. Journal of Cutaneous Pathology, 1998, 25, 89-94.	0.7	23

#	Article	IF	CITATIONS
92	Induction of apoptosis by synthetic ceramide analogues in the human keratinocyte cell line HaCaT. Experimental Dermatology, 1998, 7, 342-349.	1.4	26
93	Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. British Journal of Dermatology, 1998, 138, 77-83.	1.4	85
94	The effect of addition of calcipotriol ointment (50 mug/g) to a citretin therapy in psoriasis. British Journal of Dermatology, 1998, 138, 84-89.	1.4	103
95	Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, doubleâ€blind, randomized study. British Journal of Dermatology, 1998, 138, 254-258.	1.4	64
96	Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. British Journal of Dermatology, 1998, 139, 148-151.	1.4	44
97	The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opinion on Investigational Drugs, 1998, 7, 77-84.	1.9	19
98	Side to side comparison of topical treatment in atopic dermatitis. Archives of Disease in Childhood, 1998, 79, 149-152.	1.0	19
99	An Update on Vitamin D ₃ Analogues in the Treatment of Psoriasis. Skin Pharmacology and Physiology, 1998, 11, 2-10.	1.1	45
100	The Immunologic and Genetic Basis of Psoriasis. Archives of Dermatology, 1999, 135, 1104-10.	1.7	175
101	Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chemistry and Biology, 1999, 6, 265-275.	6.2	137
102	$1\hat{l}\pm,25$ -Dihydroxycholecalciferol and Cyclosporine Suppress Induction and Promote Resolution of Psoriasis in Human Skin Grafts Transplanted on to SCID Mice. Journal of Investigative Dermatology, 1999, 113, 1082-1089.	0.3	58
103	A Pilot Study to Assess the Safety and Efficacy of Topical Calcipotriol Treatment in Childhoodâ€fPsoriasis. Pediatric Dermatology, 1999, 16, 321-325.	0.5	37
104	Comparison of tacalcitol ointment with short-contact dithranol therapy in the treatment of psoriasis vulgaris: a randomized multicentre, open prospective study on efficacy and safety. Journal of Dermatological Treatment, 1999, 10, 93-99.	1.1	6
105	Decrease in Enkephalin Levels in Psoriatic Lesions after Calcipotriol and Mometasone Furoate Treatment. Dermatology, 1999, 198, 11-17.	0.9	11
106	Comparison of calcipotriol-PUVA with conventional PUVA in the treatment of psoriasis. Journal of Dermatological Treatment, 2000, 11, 125-130.	1.1	8
107	Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. British Journal of Dermatology, 2000, 142, 1160-1165.	1.4	22
108	Is psoriasis a T-cell disease?. Experimental Dermatology, 2000, 9, 359-375.	1.4	100
109	Topical preparations for the treatment of psoriasis: a systematic review. British Journal of Dermatology, 2000, 142, 351-364.	1.4	6

#	Article	IF	CITATIONS
110	Immunoreactivity of six monoclonal antibodies directed against 1,25-dihydroxyvitamin-D3 receptors in human skin. The Histochemical Journal, 2000, 32, 625-629.	0.6	20
111	Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ: British Medical Journal, 2000, 320, 963-967.	2.4	120
112	Calcipotriol Cream Combined with Twice Weekly Broad-Band UVB Phototherapy: A Safe, Effective and UVB-Sparing Antipsoriatric Combination Treatment. Dermatology, 2000, 200, 17-24.	0.9	70
113	The Efficacy, Safety and Tolerance of Calcitriol $3\hat{A}i\frac{1}{4}g/g$ Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol. Dermatology, 2000, 201, 139-145.	0.9	52
114	Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. Journal of the American Academy of Dermatology, 2000, 43, 61-65.	0.6	31
115	Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3for the treatment of plaque psoriasis: a pilot study. British Journal of Dermatology, 2001, 144, 500-506.	1.4	30
116	Enhancing 1α-Hydroxylase Activity with the 25-Hydroxyvitamin D-1α-Hydroxylase Gene in Cultured Human Keratinocytes and Mouse Skin. Journal of Investigative Dermatology, 2001, 116, 910-914.	0.3	18
117	Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate, 2001, 49, 224-233.	1.2	43
118	Klinische Erfahrungen mit einer kombinierten Calcipotriol/Dithranol/UVB-Therapie im Vergleich zur Dithranol/UVB-Therapie bei Psoriasis vulgaris. Aktuelle Dermatologie, 2001, 27, 21-24.	0.1	0
119	Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: A pilot study. Journal of the American Academy of Dermatology, 2002, 46, 907-913.	0.6	46
120	Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor \hat{l}_{\pm} , infliximab. Journal of the American Academy of Dermatology, 2002, 46, 886-891.	0.6	122
121	Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Archives of Dermatological Research, 2002, 294, 1-5.	1.1	35
122	Positive effect of using calcipotriol ointment with narrow-band ultraviolet B phototherapy in psoriatic patients. Photodermatology Photoimmunology and Photomedicine, 2002, 18, 131-134.	0.7	26
123	Topical preparations for the treatment of psoriasis: a systematic review. British Journal of Dermatology, 2002, 146, 351-364.	1.4	158
124	Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. International Journal of Dermatology, 2003, 42, 834-838.	0.5	27
125	Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial. British Journal of Dermatology, 2003, 149, 370-376.	1.4	29
127	The Efficacy of Calcipotriol + Acitretin Combination Therapy for Psoriasis. American Journal of Clinical Dermatology, 2003, 4, 507-510.	3.3	41
128	The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opinion on Pharmacotherapy, 2003, 4, 2347-2354.	0.9	8

#	ARTICLE	IF	CITATIONS
129	Evolution and Function of Vitamin D. Recent Results in Cancer Research, 2003, 164, 3-28.	1.8	162
130	"New treatments and old problems.". Journal of Dermatological Treatment, 2003, 14, 7-7.	1.1	2
131	A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. Journal of Dermatological Treatment, 2004, 15, 98-103.	1.1	26
132	Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. American Journal of Clinical Nutrition, 2004, 79, 362-371.	2.2	1,387
133	Antiâ€Inflammatory Effects of Tacalcitol (1,24(R)(OH) ₂ D ₃ , TVâ€02) in the Skin of TPAâ€Treated Hairless Mice. Journal of Dermatology, 2004, 31, 200-217.	0.6	17
135	Psoriasis and Other Skin Diseases. , 2005, , 1791-1804.		0
136	Calcipotriol ointment under occlusion gives a fast onset of action. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 764-765.	1.3	1
137	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. British Journal of Dermatology, 2006, 155, 800-807.	1.4	35
138	The treatment of psoriasis vulgaris: 1% topical methotrexate gel. International Journal of Dermatology, 2006, 45, 965-969.	0.5	34
141	Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. British Journal of Dermatology, 2007, 157, 369-374.	1.4	16
142	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. British Journal of Dermatology, 2008, 158, 375-381.	1.4	29
143	Clinical effect of vitamin D3 analogues is not inactivated by subsequent UV exposure. Photodermatology Photoimmunology and Photomedicine, 2008, 24, 16-18.	0.7	6
144	Vitamin D and Psoriasis. Nutrition Reviews, 1992, 50, 138-142.	2.6	5
145	Topical tazarotene vs. coal tar in stable plaque psoriasis. Clinical and Experimental Dermatology, 2010, 35, 482-486.	0.6	13
146	Nonhypercalcemic 1,25-(OH)2D3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2). Journal of Bone and Mineral Research, 1991, 6, 893-899.	3.1	36
147	Actions of calcipotriol (MC 903), a novel vitamin D3 analog, on human bone-derived cells: Comparison with 1,25-dihydroxyvitamin D3. Journal of Bone and Mineral Research, 1991, 6, 1307-1315.	3.1	20
148	Topical treatments for chronic plaque psoriasis. , 2009, , CD005028.		43
149	LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1712-1717.	1.0	32

#	Article	IF	Citations
151	Nutrition and Skin., 2011,,.		2
152	Adopted guidelines of care for the topical management of psoriasis from American and German guidelines. Journal of the Saudi Society of Dermatology & Dermatologic Surgery, 2011, 15, 5-13.	0.2	5
154	Vitamin D analogs in the treatment of psoriasis. Dermato-Endocrinology, 2011, 3, 180-186.	1.9	53
155	Psoriasis and Other Skin Diseases. , 2011, , 1891-1903.		4
157	Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet <scp>B</scp> phototherapy alone, combination of calcipotriol and narrowband ultraviolet <scp>B</scp> phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet <scp>B</scp> phototherapy more than twice a week. Journal of Dermatology, 2013, 40, 424-427.	0.6	18
158	Topical treatments for chronic plaque psoriasis. The Cochrane Library, 2013, , CD005028.	1.5	90
159	The role of vitamin D in psoriasis: a review. International Journal of Dermatology, 2015, 54, 383-392.	0.5	92
160	Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology, 2015, 11, 709-720.	1.3	28
162	Extraskeletal actions of vitamin D. Annals of the New York Academy of Sciences, 2016, 1376, 29-52.	1.8	127
163	Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 405-417.	2.6	42
164	Challenge and perspective: the relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. Photochemical and Photobiological Sciences, 2017, 16, 433-444.	1.6	18
165	Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with <scp>NBUVB</scp> phototherapy in the treatment of stable plaque psoriasis. Photodermatology Photoimmunology and Photomedicine, 2017, 33, 275-281.	0.7	9
166	Dermal Drug Selection and Development. , 2017, , .		7
167	Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2251-2262.	1.7	74
168	Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction. BMC Ophthalmology, 2017, 17, 84.	0.6	14
169	Vitamin D and the Pathophysiology of Inflammatory Skin Diseases. Skin Pharmacology and Physiology, 2018, 31, 74-86.	1.1	115
170	History of Therapies in Dermatology: Past to Present. , 2018, , 1-6.		0
171	Inhibition of IL-17–committed T cells in a murine psoriasis model by a vitamin D analogue. Journal of Allergy and Clinical Immunology, 2018, 141, 972-981.e10.	1.5	22

#	Article	IF	Citations
172	A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis. Journal of Dermatological Treatment, 2018, 29, 324-328.	1.1	19
173	Psoriasis and Other Skin Diseases. , 2018, , 1037-1051.		1
174	Therapeutic targets of vitamin D receptor ligands and their pharmacokinetic effects by modulation of transporters and metabolic enzymes. Journal of Pharmaceutical Investigation, 2020, 50, 1-16.	2.7	9
175	Use of topical calcipotriol for identification of patients with psoriasis in administrative healthcare data—a validation study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e90-e91.	1.3	6
176	Editorial: fixedâ€dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 3-4.	1.3	0
177	Relation of Dietary Fatty Acids and Vitamin D to the Prevalence of Meibomian Gland Dysfunction in Japanese Adults: The Hirado–Takushima Study. Journal of Clinical Medicine, 2021, 10, 350.	1.0	8
178	Heavy Naphthen Oil Exhibits Antipsoriatic Efficacy In Vivo and Antiproliferative as Well as Differentiation-Inducing Effects on Keratinocytes In Vitro. Archives of Dermatology, 2000, 136, 678-679.	1.7	2
180	Topical Therapy., 0, , 3965-4016.		4
183	Clinical Utility of 1,25-Dihydroxyvitamin D3 and Its Analogues for the Treatment of Psoriasis. , 2010, , 1043-1060.		3
184	Vitamin D and the skin: photobiology, physiology and therapeutic efficacy for psoriasis. , 1990, , 313-366.		21
185	Vitamin D Metabolism and Biological Function. , 1998, , 123-164.		10
186	Development of New Vitamin D Analogs. , 2005, , 1489-1510.		17
187	Structure function analysis of vitamin D analogs with C-ring modifications Journal of Biological Chemistry, 1992, 267, 3044-3051.	1.6	36
188	Safety and efficacy of calcipotriol ointment (Dovonex \hat{A}°) in treating children with psoriasis vulgaris. British Journal of Dermatology, 1996, 135, 390-393.	1.4	58
189	Topical calcipotriol in the treatment of intertriginous psoriasis. British Journal of Dermatology, 1996, 135, 647-650.	1.4	35
190	Safety and efficacy of oral calcitriol (1, 25 -dihydroxyvitamin D ₃) for the treatment of psoriasis. British Journal of Dermatology, 1996, 134, 1070-1078.	1.4	92
191	Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. British Journal of Dermatology, 1997, 136, 89-93.	1.4	45
192	A Brief History of Psoriasis Management in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 273-277.	0.6	1

#	Article	IF	CITATIONS
194	Molecular action of isoflavone genistein in the human epithelial cell line HaCaT. PLoS ONE, 2018, 13, e0192297.	1.1	24
195	Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going?. Dermato-Endocrinology, 2011, 3, 180-6.	1.9	41
196	Rationale for Use of Vitamin and Mineral Supplements. , 2001, , 1397-1426.		1
197	Rationale for Use of Vitamin and Mineral Supplements. , 2001, , .		0
198	Functions of Vitamin D. , 2004, , 181-201.		0
199	Pathogenesis of Psoriasis Vulgaris (the third part). Nishinihon Journal of Dermatology, 2006, 68, 656-664.	0.0	0
201	Potential Benefits for the Use of Vitamin and Mineral Supplements. , 2007, , 193-219.		0
202	Introduction: History of psoriasis and psoriasis therapy. , 2008, , 1-9.		2
203	Relevance of the Cutaneous Vitamin D Endocrine System for Skin Physiology and Treatment of Skin Diseases. , 2011 , , $25-42$.		0
204	History of Psoriasis., 2014, , 1-7.		2
205	Lepra vulgaris. History of Psoriasis. Journal of the Turkish Academy of Dermatology, 0, , .	0.1	1
206	Dermatological Drug Development â€" A Review of Some Important Issues. , 1990, , 1-35.		0
207	Assessing Topical Efficacy., 2017,, 69-86.		1
208	Topical therapy I: corticosteroids and vitamin D analogs. , 2008, , 41-55.		0
209	Vitamin D3 Analogues. , 0, , 127-154.		0
212	Psoriasis and other skin disorders. , 2024, , 1207-1230.		O